AbbVie (NYSE: ABBV) stock rose 4.2% after the drugmaker forecast 2025 profit above estimates, as strong sales of its newer ...

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Vertex Pharmaceuticals (VRTX) stock is rising following Food and Drug Administration (FDA) approval of Journavx, a non-opioid ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) stock is up 6% at $465.02 at last glance, after the U.S. Food and Drug ...

The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Stocks have support on better-than-expected stock earnings news. Apple is up more than +2% after forecasting a ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ (VRTX) non-opioid painkiller pill that has a low risk of addiction. Vertex is the first drugmaker in decades to gain U.S.

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (VRTX – Research Report) received a Buy rating and a $480.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...